Thousands of women with the early stages of cervical cancer could reduce their risk of developing the disease by receiving an injection against HPV, a promising investigation suggests today.
Cuelgical cancer cases in the United Kingdom have collapsed since boys aged 12 and 13, both girls and boys, were offered the vaccine and protection against the disease.
But Dutch scientists have discovered that the vaccine can play a second key role to frustrate it.
They believe that administering a dose to women with high -risk precacese cells could prevent it from becoming an invasive and deadly disease.
The trial found that in more than half of those who received the vaccine, the cells were destroyed. And after almost two years, none saw these cells reappear.
Currently, women with these hazardous cells are offered an uncomfortable operation called split with handle that the “raspa” out of the cervix.
However, surgery implies risks that include bleeding, infection and, in some cases, could cause complications in pregnancy, including premature childbirth.
Experts said today that the vaccine, “one of the most effective therapeutic vaccines” to date, could pave the way for a new protocol for women, which would mean that they would no longer have to submit to the procedure.
The symptoms of cervical cancer to which attention must be paid include unusual vaginal bleeding, pain during sexual intercourse and lumbar or pelvic pain.

Dr. Refikka Yigit, oncologist gynecologist at the Groningen University Medical Center, in the north of the country, who directed the essay, said: “As far as we know, this response rate makes VVAX001 a one of the most effective therapeutic vaccines for the most effective IAS3 associated with HPV16 “. lesions reported to date ‘
Dr. Refika Yigit, oncologist gynecologist at the Groningen University Medical Center, in the north of the country, who directed the essay, said the vaccine, that the researchers called VVAX001, was “as far as she knew”, one of “the measures most effective therapy. ” “Vaccines” for cervical predicts.
He added that, if the results were confirmed in a broader trial, it could mean that “at least half of the patients” with high -risk precancer cells “could omit surgery and avoid all their possible side effects and complications.”
According to the NHS, about eight out of 10 people will contract HPV at some point in their life and their body will eliminate it without any problem.
However, 13 of the 150 varieties The virus remain in the body for a long time and it is known that they cause 99.7 percent of cervical cancers.
There are three types of cervical predicts: IAS1 (mild), IAS2 (moderate) and IAS3 (serious). These are all abnormal cells that cover the cervix.
If it is not, approximately one third of the cases of IAS3 become cervical cancer within 10 years. The figure is approximately in the middle after 30 years.
Most IAS3 cases are caused by a specific HPV strain known as HPV16.
In phase two, 18 patients with IAS3 received three doses of vaccine three weeks apart.

The NHS cervical detection data, which date back to 2011, show that acceptance reached its highest level that year (75.7 percent) and has decreased over time.

Only 67.2 percent of girls were completely vaccinated in 2021/22, compared to a maximum of 86.7 percent in 2013/14. About 62.4 percent of children, who have been offered the vaccine in the NHS since 2019, were vaccinated in the most recent school year, according to NHS data.
All were performed routine colposcopies, a test to observe the cervix more closely.
After a 19 -week follow -up, nine saw their CIN3 cells reduce or disappear. In three cases they were completely destroyed.
Writing in the newspaper Clinical Cancer ResearchThe scientists said that of these nine patients, the size of the CIN3 tissue “was significantly reduced in all but one of the patients.”
The other nine volunteers underwent surgery, the current standard treatment.
But when four of the nine patients were operated, “no residual disease was found,” suggesting that the vaccine could also have worked for them, scientists said.
During a follow -up of approximately 20 months, “none of the patients had recurrences,” they added.
However, scientists recognized that the essay had some limitations, including a small sample size and a monitoring time of less than two years.
In the United Kingdom, the HPV vaccine offered to all girls in the eighth school year since September 2008. But eligibility only expanded to boys in the eighth school year as of September 2019.

In 2019, the YouTube star Zoe Sugg published a video of her live smear test on her channel in an attempt to encourage other women to attend their cervical exams without fear. The woman who is now 34 decided to share her exam online after a “revealing” meeting with a charity against cervical cancer.
Currently, women between 25 and 49 years in the United Kingdom are invited to cervical control in their head doctor every three years. For those who are between 50 and 64, it is offered every five years.
It could be said that detection tests are even more important for women 34 years or older, who did not receive a vaccine that protects against the vast majority of cervical cancers as part of the school program introduced in 2008.
Depending on the result of cytology, some women can be withdrawn before three -year routine intervals.
But the general acceptance of detection tests remains low. Only about 70 percent of eligible women, approximately 4.6 million, are presented to the scheduled test.
Shame is a factor, according to an investigation carried out by beneficial organizations against cervical cancer.
For half of the 1.3 million people who do not appear every year, free time at work and the search for a convenient schedule to arrange an appointment are the other reasons why they do not attend.
In 2023, the NHS promised to drastically reduce the number of women affected by cervical cancer by 2040, promising to boost both the HPV vaccine and the cervical detection exam.
However, the elimination would be technically achieved when it was diagnosed to less than four women per 100,000 each year.
As a comparison, the rate is currently at 9.5 women, which is equivalent to about 2,600 per year.
This means that around 1,100 women a year (or three a day) could still suffer the diagnostic heartbreaking if the objective of eliminating the health service is met.
Experts have attributed to the HPV vaccine the merit of helping to eradicate practically the disease among women.
However, the vaccine, like all vaccines, does not offer 100 percent protection, so the women who receive it are recommended that periodic tests be done.
(Tagstotranslate) Dailymail (T) Health